Evommune reports Q3 2025 net loss $12.5M; IPO raised $172.5M, three Phase 2 readouts due in 2026

Evommune, Inc.

Completed IPO in Nov 2025 of 10.78M shares at $16.00, raising $172.5M gross proceeds.
Three Phase 2 data readouts expected in 2026: EVO756 CSU (1H26), EVO756 AD (2H26), EVO301 AD (1H26).
Q3 2025 revenue $10.0M from Maruho collaboration; zero in prior-year quarter.
Net loss improved to $12.5M vs $15.9M YoY; cash and investments $76.0M as of Sep 30, 2025.
R&D expenses increased to $19.6M from $13.3M YoY, reflecting pipeline advancement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.